Combination therapy for HR-positive, HER2-low/ultralow breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two targeted drugs (patritumab deruxtecan and trastuzumab deruxtecan) for people with hormone receptor-positive breast cancer that has low or ultralow levels of HER2 and has spread or cannot be removed by surgery. The goal is to see if the combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is hormone receptor-positive (HR+) and has low or ultralow HER2 levels.
- Your cancer cannot be removed by surgery or has spread to other parts of the body.
- You have tried endocrine therapy, and it stopped working.
- You have been treated with a CDK4/6 inhibitor.
- You have not had chemotherapy for advanced breast cancer.
- You can provide a fresh or archived tumor sample for testing.
- You are in good overall health (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
This Phase 2 trial tests patritumab deruxtecan (U3-1402) in people with HER2-negative, hormone-receptor positive (HR+) breast cancer that cannot be removed by surgery or has spread. It’s for cancers that have progressed despite endocrine therapy plus a CDK4/6 inhibitor, aiming to shrink tumors and control the disease.
This trial tests a new drug (patritumab deruxtecan) for people with advanced or spreading cancers of the digestive system (including colorectal, bile duct, liver, and stomach/esophageal cancers). The goal is to see if it can shrink tumors or stop them from growing.
This trial tests two antibody-drug conjugates (Enhertu and Datroway) for breast cancer that is HER2-low or HER2-0. It aims to find the best treatment sequence for people whose cancer has stopped responding to prior therapy.
Hear when a new Hormone Receptor Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.